Revance Therapeutics surges after Crown tender offer extended, settles with Teoxane

seekingalpha10-28

Visivasnc/iStock via Getty Images Revance Therapeutics (NASDAQ:RVNC) jumped 29% after Crown Laboratories tender offer was extended until Nov. 1 or another mutually agreed upon date. Talks between the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2478748341?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/860617994/image_860617994.jpg?io=getty-c-w750","is_english":true,"pubTime":"2024-10-28 19:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2478748341","market":"sg","top_or_hot":-1,"title":"Revance Therapeutics surges after Crown tender offer extended, settles with Teoxane","media":"seekingalpha","content":"<div>\n<p>Visivasnc/iStock via Getty Images Revance Therapeutics (NASDAQ:RVNC) jumped 29% after Crown Laboratories tender offer was extended until Nov. 1 or another mutually agreed upon date. Talks between the ...</p>\n\n<a href=\"https://seekingalpha.com/news/4212815-revance-therapeutics-surges-after-crown-tender-offer-extended-settles-with-teoxane\">Source Link</a>\n\n</div>\n","source":"seekingalpha_trending_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Revance Therapeutics surges after Crown tender offer extended, settles with Teoxane</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRevance Therapeutics surges after Crown tender offer extended, settles with Teoxane\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-28 19:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4212815-revance-therapeutics-surges-after-crown-tender-offer-extended-settles-with-teoxane><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Visivasnc/iStock via Getty Images Revance Therapeutics (NASDAQ:RVNC) jumped 29% after Crown Laboratories tender offer was extended until Nov. 1 or another mutually agreed upon date. Talks between the ...</p>\n\n<a href=\"https://seekingalpha.com/news/4212815-revance-therapeutics-surges-after-crown-tender-offer-extended-settles-with-teoxane\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0053671581.USD","symbol_name":"摩根大通美国小盘成长股 A(dist)","start_time":0,"source_url":"https://seekingalpha.com/news/4212815-revance-therapeutics-surges-after-crown-tender-offer-extended-settles-with-teoxane","article_id":"2478748341","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/860617994/image_860617994.jpg?io=getty-c-w750"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2478748341","pubTimestamp":1730114945,"sourceInfo":{"source_id":"seekingalpha_trending_news","name":"Seeking Alpha Trending News"},"weMediaInfo":null,"summary":"Visivasnc/iStock via Getty Images Revance Therapeutics (NASDAQ:RVNC) jumped 29% after Crown Laboratories tender offer was extended until Nov. 1 or another mutually agreed upon date. Talks between the ","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU1892829315.USD":"FIDELITY FUNDS SUSTAINABLE WATER & WASTE \"A\" (USD) ACC","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","CCK":"皇冠控股","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU1803068623.USD":"TEMPLETON GLOBAL CLIMATE CHANGE \"AH1\" (USDHDG) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","BK4588":"碎股","BK4007":"制药","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","BK4126":"金属与玻璃容器","RVNC":"Revance Therapeutics Inc"},"translate_title":"皇冠要约延长并与Teoxane达成和解后Revance Therapeutics股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CCK":1,"RVNC":1},"content_text":"Visivasnc/iStock via Getty Images Revance Therapeutics (NASDAQ:RVNC) jumped 29% after Crown Laboratories tender offer was extended until Nov. 1 or another mutually agreed upon date. Talks between the companies may include discussions about the deal's offer price. The extension come after Revance (RVNC) and Teoxane came to a settlement on Thursday, according to an 8-K filing on Friday. With the agreement, Teoxane will act as the Revance’s exclusive distributor and licensee in Australia and New Zealand of certain products containing DaxibotulinumtoxinA-lanm, including DAXXIFY. \"The Company’s ongoing discussions with the Buyer Parties could result in further delays to the commencement or consummation of the Offer, or in the Company or the Buyer Parties seeking remedies in accordance with, and modifications to, the terms of the Merger Agreement, including offer price,\" according to the 8-K filing.  Crown's latest tender offer for Revance was set to expire Friday. Crown Labs has extended the tender offer deadline a few times as Revance (RVNC) continued talks with Teoxane over a dispute.  Crown Labs agreed to acquire Revance Therapeutics (RVNC) for $6.66 a share in cash in August.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2478748341"}